DUBLIN--(BUSINESS WIRE)--Jul 24, 2018--The "Investigation Report on Chinese Pregabalin Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering.

Pregabalin is a new-generation drug for neuralgia treatment. In Jul. 2004, it was approved by the European Union to treat some epileptic seizures in adults. In Dec. 2004, it was approved by the U.S. Food and Drug Administration (FDA) to treat diabetic peripheral neuralgia and postherpetic neuralgia. In 2006, generalized anxiety disorder and social anxiety disorder became new indications of Pregabalin. In 2007, Pregabalin was approved by the FDA as the first drug to treat fibromyalgia syndrome. In 2012, Pregabalin was approved by the FDA to treat spinal cord injury (SCI)-related pains. In 2010, Lyrica was approved to enter China.

According to the research, the sales value of Lyrica increased by more than 200 times from about CNY 200,000 in 2010 to over 40 million in 2017. Due to Lyrica's success, many domestic manufacturers applied for Pregabalin production. Chongqing Succeway Pharmaceutical Co., Ltd.'s Pregabalin (trade name: Lairuike) was put in the market after obtaining the production license in 2013 and is gradually taking market share from Pfizer. By sales value, in 2017, Pfizer's Lyrica had a market share of approximately 79.8%, and the rest market share was captured by the products of Chongqing Succeway Pharmaceutical Co., Ltd. It is estimated that Pfizer's Lyrica will continue to dominate the Chinese market from 2018 to 2022 but its market share will decline because of the price competition of China-made Pregabalin.

There is a continuous rise in the number of people suffering from indications for Pregabalin. For example, the number of epileptics in China has exceeded 10 million and increases by 400,000 every year. Therefore, Pregabalin has a bright prospect in China.

Key Topics Covered:

1 Relevant Concepts of Pregabalin

2 Sales of Pregabalin in China, 2013-2017

3 Major Pregabalin Manufacturers in China, 2013-2017

4 Prices of Pregabalin in China, 2017-2018

5 Prospects of Chinese Pregabalin Market, 2018-2022

Companies Mentioned

Chongqing Succeway Pharmaceutical Co., Ltd. Pfizer

For more information about this report visit https://www.researchandmarkets.com/research/bq2dpg/investigation?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180724005655/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs,Analgesics

KEYWORD: ASIA PACIFIC CHINA

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/24/2018 10:51 AM/DISC: 07/24/2018 10:51 AM

http://www.businesswire.com/news/home/20180724005655/en